


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Substitute for form 1449A/PTO		<b>Complete if Known</b>	
		<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number: 10/049,556 Filing Date: February 12, 2002 Intern. Application Number: PCT/AU00/00982 Intern. Filing Date: 08/17/00 First Named Inventor: DAVID G. LITTLE Group Art Unit: Unassigned Examiner Name: Unassigned Attorney Docket Number: RICE006	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>3</sup> Kind Code <sup>3</sup> (if known)				
K		B7	WO96/39150A	Merck & Co., Inc.	12/12/1996		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
K	C1	ABSTRACT: LOMBARDI, entitled "Clinical trials with bisphosphonates" Ann Ital Med Int. 1992 Jul-Sep; 7(3 Suppl): 158S-165S.	
K	C2	GOODSHIP et al., entitled "Use of Bisphosphonate (pamidronate) to modulate fracture repair in ovine bone," Ann Oncology 1994; 5 Suppl 7:S53-5.	
K	C3	LI et al. entitled "Effect of Bisphosphonate (Incadronate) on Fracture Healing of Long Bones in Rats," J Bone Miner Res. Vol. 14, Number 6, (1999): 969-79.	
K	C4	RUSSELL et al., entitled "Bisphosphonates: from the laboratory to the clinic and back again," Bone 1999 Jul; 25(1):97-106	
K	C5	GLORIEUX et al., entitled "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta," N. Engl. J Med 1998; Number 14, 339:947-52	
K	C6	RAGGIO et al. entitled, "Alendronate reduces fractures without increasing bone strength in a growing mouse model of osteogenesis imperfecta," Proceedings of Paediatric Orthopaedic Society of North America May 1999. (Paper No. 66)	
K	C7	GIULIANI et al., entitled "Bisphosphonates Stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo," Bone 1998, May; Vol. 22 (5): 455-61.	
K	C8	MAYOR P., et al., entitled "Zolendroic acid is superior to pamidronate in the treatment of tumour-induced hypercalcaemia: a pooled analysis," Journal of Clinical Oncology, Vol. 19, No. 2, January 15, 2001: pp. 558-567	

Examiner Signature	<i>Shah</i>	Date Considered	04/17/06
--------------------	-------------	-----------------	----------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/049,556
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Filing Date	May 7, 2002
				First Named Inventor	LITTLE, DAVID GRAHAM
				Group Art Unit	1617
				Examiner Name	CRIARES, THEODORE J.
				Attorney Docket Number	RICE-006
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
K		5,853,759		Katdare et al.	12-29-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature	<i>Stallik</i>	Date Considered	04/17/06
-----------------------	----------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this .



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	Unassigned		
		Filing Date	Herewith		
		First Named Inventor	LITTLE, DAVID G.		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	RICE-006

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>2</sup>	Number <sup>2</sup>	Kind Code <sup>2</sup> (if known)				
Ks	B1	WO	93/11786		Procter & Gamble Pharmaceuticals, Inc.	06/24/1993		
Ks	B2	WO	94/21266		Leiras Oy	09/24/1994		
Ks	B3	WO	95/28936		Merck & Co., Inc.	11/02/1995		
Ks	B4	WO	96/39150		Merck & Co., Inc.	12/12/1996		
Ks	B5	WO	96/39151		Merck & Co., Inc.	12/12/1996		
Ks	B6	WO	98/00438		The University of Liverpool	01/08/1998		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city, and/or country, where published</small>	T <sup>3</sup>

Examiner Signature	SLANT 'K	Date Considered	04/17/06
-----------------------	----------	--------------------	----------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.